Braveheart is one of many startups to recently turn to China-originated companies to build a pipeline. Its licensing deal with Hengrui, worth potentially more than $1 billion, was one of at least 20 between Chinese biotechs and privately held U.S. or European companies this year, according to BioPharma Dive data.
These deals are enabling new companies to start up with drugs that, in many instances, are already in clinical testing and seen as potentially better versions of other therapies either in testing or on the market. They’ve become so prominent they’ve caught the attention of lawmakers in Washington D.C., which just last week held a hearing discussing reforms that might help U.S. research labs and the companies built around their work better compete.
Read More – Armis Closes $435M Pre-IPO Funding Round at $6.1 Billion Valuation
Murdoch noted how he pursued an in-licensing strategy in forming HI-Bio, which was built around a drug acquired from Germany. With Braveheart, the executive team and the funds supporting it looked “around the world,” not just China, for promising drugs, he said.
“This particular molecule stood out in that search for its potential,” he said, “so this is really a story about finding the most compelling molecule.”
That molecule is a possible threat to Camzyos, a Bristol Myers Squibb medicine that in 2022 became the first approved treatment for the “obstructive” and more common form of the progressive heart condition hypertrophic cardiomyopathy. Camzyos is currently still the only drug available for the disease and generated $843 million in sales over the first nine months of the year. But it may soon face competition. A drug from Cytokinetics could be approved later this year and others, including Braveheart’s, are advancing through testing.
All of these medicines are so-called cardiac myosin inhibitors. They’re designed to make the heart’s contractions less forceful, which, in turn, is meant to help alleviate symptoms associated with the condition. But while these drugs have helped improve heart function and how patients feel, there’s still a “significant unmet need,” Murdoch told BioPharma Dive.
Many patients still have evidence of a blockage, or that their hearts have a reduced ability to pump out blood, he said. The complex dosing schedule and risk mitigation protocol associated with Camzyos has also limited uptake. Additionally, none of the experimental medicines have yet succeeded in a Phase 3 study in the “non-obstructive” type of HCM, which is estimated to account for about a third of the people with the condition.
Braveheart, for its part, claimed in a statement that BHB-1893 has the potential to be a “best-in-class molecule” that enhances the “safety, efficacy, and convenience of care” for patients and doctors. Phase 1 data were presented at a medical meeting in August and demonstrated “rapid and clinically meaningful” impact on blood flow out of the heart as well as a safety profile supporting a “simple dosing regime,” the company said.
Read More – Mindsmith Raises $4.1M in Seed Funding
